ABIVAX Société Anonyme Management
Management criteria checks 1/4
ABIVAX Société Anonyme's CEO is Marc M. de Garidel, appointed in May 2023, has a tenure of 1.58 years. total yearly compensation is €793.97K, comprised of 45.3% salary and 54.7% bonuses, including company stock and options. directly owns 0.06% of the company’s shares, worth €268.94K. The average tenure of the management team and the board of directors is 1.3 years and 3.4 years respectively.
Key information
Marc M. de Garidel
Chief executive officer
€794.0k
Total compensation
| CEO salary percentage | 45.3% |
| CEO tenure | 1.6yrs |
| CEO ownership | 0.06% |
| Management average tenure | 1.3yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Does ABIVAX Société Anonyme (EPA:ABVX) Have A Healthy Balance Sheet?
Oct 03
Is ABIVAX Société Anonyme (EPA:ABVX) A Risky Investment?
Apr 24Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?
Jun 07An Intrinsic Calculation For ABIVAX Société Anonyme (EPA:ABVX) Suggests It's 28% Undervalued
Dec 11Is ABIVAX Société Anonyme (EPA:ABVX) Using Too Much Debt?
Jun 06A Quick Analysis On ABIVAX Société Anonyme's (EPA:ABVX) CEO Salary
Dec 31
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€177m |
| Mar 31 2024 | n/a | n/a | -€163m |
| Dec 31 2023 | €794k | €359k | -€148m |
Compensation vs Market: Marc M.'s total compensation ($USD827.83K) is above average for companies of similar size in the French market ($USD540.83K).
Compensation vs Earnings: Insufficient data to compare Marc M.'s compensation with company performance.
CEO
Marc M. de Garidel (66 yo)
1.6yrs
Tenure
€793,971
Compensation
Mr. Marc M. P. de Garidel, M.B.A., serves as Director of Claris Biotherapeutics, Inc. He has been CEO at ABIVAX Société Anonyme since May 5, 2023 and serves as its Director. He had been Interim Chair of th...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.6yrs | €793.97k | 0.060% € 268.9k | |
| Founder & Director | no data | €35.00k | 0.43% € 1.9m | |
| EVP, CFO & Board Secretary | 7.9yrs | no data | 0.00059% € 2.6k | |
| Chief Scientific Officer | 1.3yrs | no data | 0.056% € 252.2k | |
| Senior Vice President of Investor Relations | 1.3yrs | no data | no data | |
| Chief People & Compliance Officer | 1.5yrs | no data | no data | |
| Chief Business Officer | no data | no data | 0% € 0 | |
| Executive Vice President of Process Development & Manufacturing | 1.3yrs | no data | no data | |
| VP & Global Head of Quality | less than a year | no data | no data | |
| Senior Vice President of Finance | no data | no data | no data | |
| VP & Global Head of Medical Affairs | no data | no data | no data | |
| VP & Global Head of Biometrics | no data | no data | no data |
1.3yrs
Average Tenure
57.5yo
Average Age
Experienced Management: ABVX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.6yrs | €793.97k | 0.060% € 268.9k | |
| Founder & Director | 11yrs | €35.00k | 0.43% € 1.9m | |
| Chair of the Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.4yrs | €44.33k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 5.2yrs | €4.94k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 1.4yrs | €35.24k | no data | |
| Independent Non-Executive Director | 7.5yrs | €135.16k | 0% € 0 | |
| Chairman of Scientific Advisory Board | 6.5yrs | no data | no data |
3.4yrs
Average Tenure
63.5yo
Average Age
Experienced Board: ABVX's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 02:20 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ABIVAX Société Anonyme is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Le Berrigaud | Bryan Garnier & Co |
| Oscar Haffen Lamm | Bryan Garnier & Co |
| Julian Harrison | BTIG |